This article was originally published in The Tan Sheet
Enzymatic Therapy acquires distribution rights for menopausal treatment product Remifemin from GlaxoSmithKline, according to a May 25 announcement. GSK will transfer rights for the product to the Green Bay, Wisc.-based firm when the transaction becomes effective June 20. Enzymatic Therapy says it will partner with German Remifemin manufacturer Shaper & Brummer to boost product distribution and market share. The firm distributed the hormone-free menopausal therapy between 1995 and 2000, prior to the product's entry to the mass market under GSK...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.